Human IgG F(ab')2 Antibody

SKU: orb346221

Description

Human IgG F(ab')2 Antibody

Research Area

Protein Biochemistry

Images & Validation

• Tested Applications: ELISA, SDS-PAGE, WB
• Application Notes:
  Human IgG F(ab')2 Fragment has been tested in SDS-Page and ELISA and can be utilized as a control or standard reagent in SDS, Western Blotting, and ELISA experiments.

Key Properties

• Source: Human
• Biological Origin: Human
• Isotype: IgG F(ab')2
• Conjugation: Unconjugated
• Purity: Human IgG F(ab')2 was prepared from normal serum by a multi-step process which includes delipidation, salt fractionation, ion exchange chromatography and pepsin digestion followed by chromatographic separation and extensive dialysis against the buffer stated above. Assay by immunoelectrophoresis resulted in a single precipitin arc against anti-Human Serum, anti-Human IgG and anti-Human IgG F(ab’)2. No reaction was observed against anti-Human IgG F(c) or anti-Pepsin.

Storage & Handling

• Storage: Store vial at 4° C prior to opening. This product is stable 4° C as an undiluted liquid. Dilute only prior to immediate use. For extended storage mix with an equal volume of glycerol, aliquot contents and freeze at -20° C or below. Avoid cycles of freezing and thawing.
• Form/Appearance: Liquid (sterile filtered)
• Buffer/Preservatives: Preservative: 0.01% (w/v) Sodium Azide. Stabilizer: None; Buffer: 0.02 M Potassium Phosphate, 0.15 M Sodium Chloride, pH 7.2
• Concentration: 2.0 mg/mL
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Human Immunoglobulin G F(ab')2 Fragment, IgG Fab2

Anti-hinge antibodies interfere with the detection of anti-drug antibodies. A total of 115 samples from patients with no previous adalimumab exposure (A) and 91 samples from patients treated with adalimumab (B) were evaluated by flow cytometry and resulted in high anti-adalimumab MFIs. The addition of 20 µg/ml of human IgG F(ab')2 reduced the anti-adalimumab MFI signals in both naïve and adalimumab-treated patients. (C) There was no difference between adalimumab-naïve vs. treated groups in MFI fold-change or proportion of patients positive for anti-hinge antibodies. Anti-hinge–positive status was defined as ≥ 1.5-fold change as shown by the horizontal line.

Dose dependent inhibition curves generated with six different FcγR assays. Four different set of samples were tested to show the specificity and subclass specific binding. Analytes tested are (1) human IgG subclasses IgG1, IgG2, IgG3, IgG4; (2) human IgG; (3) Fc, Fab, and F(ab)2 domains; and (4) human serum albumin (HSA). Data represent the mean ± standard error of triplicate experiments. IC50 (nM) values calculated from the inhibition curves are shown in the Table. IC50 values are in nM. *For FcγRIIb IC50 values are intended only for qualitative purposes as mentioned in the text. n.d. not determined.

SDS-Page of Human IgG F(ab')2 Fragment. Lane 1: Human F(ab')2 – Non-Reduced. Lane 2: Human F(ab')2 – Reduced. Load: 1.0 µg per lane. Predicted/observed size: 25 kDa – Reduced, 120 kDa – Non-Reduced for F(ab')2 fragment. Other band(s): None.